within Pharmacolibrary.Drugs.M_MusculoSkeletalSystem.M03A_MuscleRelaxantsPeripherallyActingAgents.M03AC03_Vecuronium;

model Vecuronium
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_2C(
    weight = 70,
    F = 1,
    Cl = 4.2e-06,
    adminDuration = 600,
    adminMass = 0.1 / 1000000,
    adminCount = 1,
    Vd = 0.00020999999999999998,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    Vdp = 0.00016,
    k12 = 3.666666666666667e-06,
    k21 = 3.666666666666667e-06);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Vecuronium</td></tr><tr><td>ATC code:</td><td>M03AC03</td></tr><td>route:</td><td>intravenous</td></tr>
    <tr><td>compartments:</td><td>2</td></tr>
    <tr><td>dosage:</td><td>0.1</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>0.21</td><td>L</td></tr>
    <tr><td>clearance:</td><td>3.6</td><td>mL/min/kg</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Vecuronium is a non-depolarizing neuromuscular blocker of the aminosteroid group, used as an adjunct to general anesthesia to facilitate endotracheal intubation and provide skeletal muscle relaxation during surgery or mechanical ventilation. It is typically administered intravenously and is approved for clinical use.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters in healthy adult surgical patients following intravenous bolus administration.</p><h4>References</h4><ol><li><p>Caldwell, JE, et al., &amp; Sessler, DI (2000). Temperature-dependent pharmacokinetics and pharmacodynamics of vecuronium. <i>Anesthesiology</i> 92(1) 84–93. DOI:<a href=\"https://doi.org/10.1097/00000542-200001000-00018\">10.1097/00000542-200001000-00018</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/10638903/\">https://pubmed.ncbi.nlm.nih.gov/10638903</a></p></li><li><p>Keating, GM (2016). Sugammadex: A Review of Neuromuscular Blockade Reversal. <i>Drugs</i> 76(10) 1041–1052. DOI:<a href=\"https://doi.org/10.1007/s40265-016-0604-1\">10.1007/s40265-016-0604-1</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/27324403/\">https://pubmed.ncbi.nlm.nih.gov/27324403</a></p></li><li><p>Onrust, SV, &amp; Foster, RH (1999). Rapacuronium bromide: a review of its use in anaesthetic practice. <i>Drugs</i> 58(5) 887–918. DOI:<a href=\"https://doi.org/10.2165/00003495-199958050-00011\">10.2165/00003495-199958050-00011</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/10595867/\">https://pubmed.ncbi.nlm.nih.gov/10595867</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.M.M03AC03 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Vecuronium;
